Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 2, 2009, Pages

  Guinto, Pia J ^a   Haim, Todd E ^a   Dowell Martino, Candice C ^a   Sibinga, Nathaniel ^a   Tardiff, Jil C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium handling; Cardiac troponin T; Contractility; Familial hypertrophic cardiomyopathy

Indexed keywords

CALCIUM ION; PHOSPHOLAMBAN; TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CARDIOMYOPATHY; CONTROLLED STUDY; HEART LEFT VENTRICLE MUSCLE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSGENIC MOUSE;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HOMEOSTASIS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SODIUM-CALCIUM EXCHANGER; TROPONIN T;

EID: 68049115750     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01143.2008     Document Type: Article

References (53)

1. Anderson ME. Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther 106: 39-55, 2005.
2. Bers DM. Beyond beta blockers. Nat Med 11: 379-380, 2005.
3. 2+ transport. Circ Res 93: 487-490, 2003.
4. 2+ transport. Circ Res 92: 769-776, 2003.
5. 2+ activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol 280: H705-H713, 2001.
6. Chandra M, Tschirgi ML, Tardiff JC. Increase in tension-dependent ATP consumption induced by cardiac troponin T mutation. Am J Physiol Heart Circ Physiol 289: H2112-H2119, 2005. (Pubitemid 41507363)
7. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations. Circ Res 94: 1235-1241, 2004. (Pubitemid 38656410)
8. 2+-handling in failing human myocardium. J Mol Cell Cardiol 33: 1345-1353, 2001.
9. Diedrichs H, Frank K, Schneider CA, Burst V, Hagemeister J, Zobel C, Ehmsen JM. Increased functional importance of the Na,Ca-exchanger in contracting failing human myocardium but unchanged activity in isolated vesicles. Int Heart J 48: 755-766, 2007.
10. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 33: 1596-1601, 1999.
11. Ertz-Berger BR, He H, Dowell C, Factor SM, Haim TE, Nunez S, Schwartz SD, Ingwall JS, Tardiff JC. Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice. Proc Natl Acad Sci USA 102: 18219-18224, 2005. (Pubitemid 41798528)
12. Evans CC, Pena JR, Phillips RM, Muthuchamy M, Wieczorek DF, Solaro RJ, Wolska BM. Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 279: H2414-H2423, 2000.
13. Fatkin D, Graham RM. Molecular mechanisms of inherited cardiomyopathies. Physiol Rev 82: 945-980, 2002.
14. Forissier JF, Carrier L, Farza H, Bonne G, Bercovici J, Richard P, Hainque B, Townsend PJ, Yacoub MH, Faure S, Dubourg O, Millaire A, Hagege AA, Desnos M, Komajda M, Schwartz K. Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. Circulation 94: 3069-3073, 1996. (Pubitemid 26427467)
15. Gomes AV, Barnes JA, Harada K, Potter JD. Role of troponin T in disease. Mol Cell Biochem 263: 115-129, 2004.
16. Guinto PJ, Manning EP, Schwartz SD, Tardiff JC. Computational characterization of mutations in cardiac troponin T known to cause familial hypertrophic cardiomyopathy. J Theor Comp Chem 6: 413-419, 2007.
17. Haghighi K, Gregory KN, Kranias EG. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322: 1214-1222, 2004. (Pubitemid 39164651)
18. Haim TE, Dowell C, Diamanti T, Scheuer J, Tardiff JC. Independent FHC-related cardiac troponin T mutations exhibit specific alterations in myocellular contractility and calcium kinetics. J Mol Cell Cardiol 42: 1098-1110, 2007. (Pubitemid 46829199)
19. 2+ sensitivity of cardiac muscle contraction. J Biol Chem 279: 14488-14495, 2004.
20. Harrer JM, Kiss E, Kranias EG. Application of the immunoblot technique for quantitation of protein levels in cardiac homogenates. Biotechniques 18: 995-998, 1995.
21. Hinkle A, Goranson A, Butters CA, Tobacman LS. Roles for the troponin tail domain in thin filament assembly and regulation. A deletional study of cardiac troponin T. J Biol Chem 274: 7157-7164, 1999. (Pubitemid 129505004)
22. Hinkle A, Tobacman LS. Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem 278: 506-513, 2003. (Pubitemid 36043603)
23. Hoshijima M, Knoll R, Pashmforoush M, Chien KR. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J Am Coll Cardiol 48: A15-A23, 2006. (Pubitemid 44755024)
24. 2+ transients of mouse heart myocytes conditionally expressing PKCβ. Am J Physiol Cell Physiol 280: C1114-C1120, 2001.
25. Janssen PM, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol 282: H499-H507, 2002. (Pubitemid 34654973)
26. 2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J Biol Chem 278: 25063-25071, 2003.
27. 2+ ATPase enzymatic properties using mouse cardiac tissue homogenates. Anal Biochem 269: 236-244, 1999.
28. 2+ homeostasis and cardiac contractility. Am J Physiol Heart Circ Physiol 290: H599-H606, 2006.
29. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW 2nd, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 97: 533-539, 1996. (Pubitemid 26039421)
30. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343: 1688-1696, 2000.
31. 2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. J Mol Cell Cardiol 43: 354-361, 2007.
32. 2+-dependent action potential remodeling. Circ Res 92: 428-436, 2003.
33. Knollmann BC, Potter JD. Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy. Trends Cardiovasc Med 11: 206-212, 2001.
34. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21, 2005. (Pubitemid 40357865)
35. Montgomery DE, Chandra M, Huang Q, Jin J, Solaro RJ. Transgenic incorporation of skeletal TnT into cardiac myofilaments blunts PKC-mediated depression of force. Am J Physiol Heart Circ Physiol 280: H1011-H1018, 2001. (Pubitemid 32537860)
36. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol 29: 549-555, 1997. (Pubitemid 27116096)
37. Nicol RL, Frey N, Olson EN. From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. Annu Rev Genomics Hum Genet 1: 179-223, 2000.
38. 2+ load attributable to the predominance of forward mode block. Circ Res 102: 1398-1405, 2008.
39. Palm T, Graboski S, Hitchcock-DeGregori SE, Greenfield NJ. Disease-causing mutations in cardiac troponin T: identification of a critical tropomyosin-binding region. Biophys J 81: 2827-2837, 2001. (Pubitemid 33020068)
40. Palmer BM, Fishbaugher DE, Schmitt JP, Wang Y, Alpert NR, Seidman CE, Seidman JG, VanBuren P, Maughan DW. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol 287: H91-H99, 2004. (Pubitemid 38802340)
41. Revera M, Van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. Long-term follow-up of R403WMYH7 and R92WTNNT2 HCM families: mutations determine left ventricular dimensions but not wall thickness during disease progression. Cardiovasc J Afr 18: 146-153, 2007. (Pubitemid 47345203)
42. Revera M, van der Merwe L, Heradien M, Goosen A, Corfield VA, Brink PA, Moolman-Smook JC. Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy. Cardiovasc Res 77: 687-694, 2008. (Pubitemid 351301858)
43. 2+ uptake as a primary cause of heart failure. Cardiovasc Res 56: 248-259, 2002.
44. 2+ sensitivity increase. J Physiol 575: 201-213, 2006.
45. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111: 859-867, 2003. (Pubitemid 37074961)
46. 2+-saturated form. Nature 424: 35-41, 2003.
47. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA. Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104: 469-481, 1999. (Pubitemid 29534331)
48. Tobacman LS, Lin D, Butters C, Landis C, Back N, Pavlov D, Homsher E. Functional consequences of troponin T mutations found in hypertrophic cardiomyopathy. J Biol Chem 274: 28363-28370, 1999. (Pubitemid 129504704)
49. Tobacman LS, Nihli M, Butters C, Heller M, Hatch V, Craig R, Lehman W, Homsher E. The troponin tail domain promotes a conformational state of the thin filament that suppresses myosin activity. J Biol Chem 277: 27636-27642, 2002. (Pubitemid 34966706)
50. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, Matsumori A, Moravec CS, Seidman JG. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 332: 1058-1064, 1995.
51. Watkins H, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet 4: Spec No. 1721-1727, 1995.
52. 2+ transients but accelerates their decay in rat single cardiac myocytes. Am J Physiol Heart Circ Physiol 285: H470-H475, 2003.
53. Zhang R, Khoo MS, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11: 409-417, 2005. (Pubitemid 40562331)